Zacks: Analysts Anticipate Vascular Biogenics Ltd. (NASDAQ:VBLT) Will Post Earnings of -$0.12 Per Share

Analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLTGet Rating) to report ($0.12) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have issued estimates for Vascular Biogenics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Vascular Biogenics also reported earnings per share of ($0.12) in the same quarter last year. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Vascular Biogenics will report full-year earnings of ($0.47) per share for the current fiscal year, with EPS estimates ranging from ($0.50) to ($0.41). For the next fiscal year, analysts expect that the business will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.58) to ($0.44). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Vascular Biogenics.

Vascular Biogenics (NASDAQ:VBLTGet Rating) last announced its quarterly earnings results on Wednesday, March 23rd. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.04). The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.20 million. Vascular Biogenics had a negative return on equity of 63.08% and a negative net margin of 3,895.83%. During the same quarter in the prior year, the company earned ($0.15) earnings per share.

A number of equities research analysts have recently issued reports on VBLT shares. started coverage on Vascular Biogenics in a research note on Tuesday, April 5th. They issued a “hold” rating for the company. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $5.05.

NASDAQ:VBLT traded up $0.03 on Monday, hitting $1.92. 398,722 shares of the stock were exchanged, compared to its average volume of 164,544. The stock has a market cap of $133.11 million, a PE ratio of -4.27 and a beta of 1.15. The stock has a fifty day moving average of $1.45 and a 200-day moving average of $1.84. Vascular Biogenics has a fifty-two week low of $1.10 and a fifty-two week high of $3.04.

Large investors have recently added to or reduced their stakes in the business. Two Sigma Advisers LP bought a new position in Vascular Biogenics during the 3rd quarter worth approximately $30,000. Spectrum Planning & Advisory Services Inc. bought a new position in Vascular Biogenics during the 4th quarter worth approximately $32,000. Goldman Sachs Group Inc. lifted its holdings in Vascular Biogenics by 44.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 16,556 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 5,069 shares during the last quarter. Jane Street Group LLC bought a new position in Vascular Biogenics during the 3rd quarter worth approximately $42,000. Finally, Millennium Management LLC bought a new stake in shares of Vascular Biogenics in the 2nd quarter worth approximately $89,000. 47.07% of the stock is currently owned by institutional investors.

About Vascular Biogenics (Get Rating)

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications.

Further Reading

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.